Metastatic Castration Sensitive Prostate Cancer (mCSPC) research hub

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)